The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Adult Malignant Glioma Therapeutics Market Expected To Scale Between 2026 And 2030?
The adult malignant glioma therapeutics market size has seen substantial growth in recent times. It is anticipated to increase from $2.47 billion in 2025 to $2.7 billion in 2026, at a compound annual growth rate (CAGR) of 9.1%. The expansion observed historically is attributable to a scarcity of therapeutic choices for malignant gliomas, continued dependence on standard chemotherapy and radiotherapy, a rising incidence of adult brain tumors, the growth of hospital oncology services, and increased awareness regarding glioma treatment requirements.
The adult malignant glioma therapeutics market is poised for significant expansion in the coming years. This market is projected to reach $3.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. Key drivers for this anticipated growth include the advancement of targeted molecular therapies, the broadening of clinical trials for innovative glioma treatments, increased funding in precision oncology, growing partnerships between biotechnology firms and healthcare providers, and the integration of sophisticated radiotherapy and combination therapy methods. Noteworthy trends shaping this period encompass the escalating creation of targeted glioma therapies, the expanding use of combined treatment strategies, the wider application of experimental and personalized medicine, an increasing emphasis on enhancing patient quality of life, and the greater implementation of advanced radiotherapy techniques.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Primary Drivers Are Impacting The Adult Malignant Glioma Therapeutics Market Growth?
Government funding allocated to support brain cancer research is anticipated to propel the growth of the adult malignant glioma therapeutics market. This financial support, provided by federal, state, or local government entities, extends to various organizations, initiatives, projects, programs, or individuals. Such funding proves beneficial for adult malignant glioma therapeutics by facilitating the development of novel treatments, supporting customized drug development, enabling efforts targeting pyrimidine synthesis, and aiding in orphan drug approval processes. For instance, in June 2023, the Australian Department of Health and Aged Care, an Australia-based government authority, launched the Australian Brain Cancer Mission, committing a fund of $136.66 million to advance brain cancer research. The objective of this initiative is to double the survival rates and thereby enhance the quality of life for patients diagnosed with brain cancer, including anaplastic astrocytoma. Therefore, government funding directed towards brain cancer research actively drives the adult malignant glioma therapeutics market.
How Is The Adult Malignant Glioma Therapeutics Market Segmented Across Different Segment Categories?
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users
Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies
Which Trends Are Shaping Growth In The Adult Malignant Glioma Therapeutics Market?
Leading companies within the adult malignant glioma therapeutics market are engaged in developing innovative products, such as small molecule targeted degraders, with the aim of delivering reliable customer service. A small-molecule targeted degrader operates as a pharmaceutical agent utilizing small molecules to prompt the degradation of specific proteins by concurrently targeting a protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, secured orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17, intended for the treatment of glioblastoma (GBM). This particular compound is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, both of which have been implicated in the pathogenesis of various cancers, including GBM. BEA-17 exerts its effect by degrading LSD1 and CoREST, which subsequently leads to the reactivation of tumor suppressor genes and the suppression of cancer cell growth.
Which Organizations Play A Role In The Adult Malignant Glioma Therapeutics Market Landscape?
Major companies operating in the adult malignant glioma therapeutics market are Johnson & Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genentech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
Get The Full Adult Malignant Glioma Therapeutics Market Report:
Which Geographic Region Dominates The Adult Malignant Glioma Therapeutics Market?
North America was the largest region in the adult malignant glioma therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Adult Malignant Glioma Therapeutics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Adult Malignant Glioma Therapeutics Market 2026, By The Business Research Company
Brain Tumor Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Glioma Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report
Pontine Glioma Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model